![]() In addition, hepatitis B surface antigen and anti-hepatitis C virus status were also obtained before starting anti-TNF therapy. Screening for latent tuberculosis (TB) included chest X-ray, interferon gamma release assay (“Quantiferon-TB-Gold“), and Mantoux test (1 TU). Women with pregnancy or who were breastfeeding were also excluded from the study. Patients with active tuberculosis, current or past history of hepatitis B, hepatitis C or human immunodeficiency virus, demyelinating disease, alcohol abuse, psychiatric illness, symptoms of severe and progressive or uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurological, or cerebral disease, congestive heart failure, history of any form of cancer within the past 10 years, history of serious infection requiring hospitalization in the past 6 months, and history of any surgery in the past 12 weeks.Patients who did not complete at least 12 weeks of etanercept biosimilar therapy or.Primary endpoint was BASDAI 4 Bath Ankylosing Spondylitis Disease Activity Index ) despite a 1-month trial of at least two NSAIDs (for axial symptoms only) with or without 3-month trial of DMARDs (for peripheral joint symptoms). For Etacept, week 52 and 104 data were also available. BASDAI, Bath Ankylosing Spondylitis Functional Index, and ASDAS and NSAID index were noted at baseline, 12, and 24 weeks. Patients achieving “major improvement” after 12 weeks (Ankylosing Spondylitis Disease Activity Score reduction by >2 points) received the dose every 2 weeks subsequently. Etanercept biosimilar (50 mg) was administered weekly for the first 12 weeks. Those with active disease (Bath Ankylosing Spondylitis Disease Activity Index >4), despite 1-month trial of two non-steroidal anti-inflammatory drugs (NSAIDs) (axial) and/or 3-month trial of disease modifying anti-rheumatic drugs (peripheral), received anti-TNF therapy. Methods: Clinical record of patients with axial and/or peripheral SpA (Assessment of SpA International Society criteria) registered during April 2013–September 2016 was retrieved. We present retrospective analysis of our experience with 2 etanercept biosimilars (Etacept and Intacept). If you have low body weight, you may be at increased risk of bleeding, and drinking alcohol can increase the risk of stomach bleeding.Background: Antitumor necrosis factor (TNF) drugs are highly efficacious in spondyloarthritis (SpA). ![]() Tell your doctor what else you are taking to make sure it is safe. Some medicines should not be used with Evaparin Injection. You should not take it if you have any current bleeding. Look out for symptoms and tell your doctor if you are worried.īefore using this medicine, you should tell your doctor if you have high blood pressure, diabetes, or have had a recent stroke. Bleeding can be dangerous and may not be obvious. A severe stomach ache could be a sign of bleeding in the stomach. A severe headache could be a sign of bleeding in the brain. The most common side effect of this medicine include bleeding, headache, increased blood platelets, and increased liver enzymes. ![]() While taking this medicine you should avoid doing things that increase your risk of bleeding or injury. If you stop taking it, you could get a blood clot. It is important to keep using this medicine even if you do not notice any symptoms because it is preventing future harm. It may also be based on your age and weight. The dose and length of treatment are based on your medical condition, your response to the medicine, and what you are being treated for. It is also helpful in the prevention of blood clots in veins, a condition called deep vein thrombosis, and pulmonary embolism.Įvaparin Injection is injected under the skin by a doctor or nurse. It stops the existing clots from getting any bigger and restricts the formation of any new clot. Evaparin Injection is an anticoagulant used to prevent and treat harmful blood clots.
0 Comments
Leave a Reply. |